Glutaric acidemia I and the striatum

The clinical story of glutaric acidemia type I is the story of a metabolic condition that, before screening, produced one of the more cinematically dramatic injuries in pediatric neurology: a previously well child with a head circumference larger than expected, who in the second year of life develops a febrile illness, returns from the emergency department, and over the following days loses motor control and develops dystonia that does not improve. The brain MRI shows striatal injury. The metabolic workup, sometimes done years later, returns elevated glutaric acid. The damage was done in a single illness in a single week.

After universal newborn screening, that picture has largely disappeared in screened populations. The same condition, identified at birth and managed with a lysine-restricted diet plus an aggressive emergency protocol during febrile illness, produces children whose striatum stays intact. The screen and the protocol together changed the clinical anchor of the disease from a movement disorder to a managed metabolic condition.

What GA-1 is

Glutaric acidemia type I, GA-1, is an autosomal recessive organic acid disorder caused by deficiency of glutaryl-CoA dehydrogenase (GCDH), encoded by GCDH on chromosome 19p13. GCDH catalyzes the conversion of glutaryl-CoA to crotonyl-CoA in the catabolic pathway of lysine, hydroxylysine, and tryptophan. When GCDH activity fails, glutaryl-CoA, glutaric acid, and 3-hydroxyglutaric acid accumulate. The 3-hydroxyglutaric acid in particular is toxic to the striatum.

Macrocephaly is present at birth in a substantial fraction of affected children and is often the first finding documented at well-baby visits before the metabolic disease is recognized. Brain MRI in the first months of life often shows mild abnormalities of frontotemporal atrophy and widened sylvian fissures even before any clinical deterioration.

The encephalopathic crisis is the central clinical event of untreated or undertreated GA-1. It typically occurs between 6 and 24 months of age, triggered by a febrile illness, infection, surgery, or other catabolic stress. Over hours to a few days, the affected child loses acquired motor skills, develops dystonia and choreoathetosis, and is left with a movement disorder that does not improve. The neurological injury is permanent. A smaller proportion of children develop striatal injury insidiously, without an identifiable acute crisis, through the same mechanism applied chronically.

Two biochemical phenotypes are recognized. High excretors show markedly elevated urinary glutaric acid even between episodes. Low excretors have urine organic acids that may appear normal between episodes. The C5DC marker on the dried blood spot detects both, and the biochemical phenotype does not predict clinical severity.

Reported live-birth incidence in unselected populations is roughly 1 in 100,000. Founder populations show dramatically higher rates: the Old Order Amish of Pennsylvania at roughly 1 in 300, the Lumbee Native Americans of North Carolina, the Oji-Cree of Canada, the Irish Traveller community, and several populations in Saudi Arabia.

Detection

Newborn screening uses tandem mass spectrometry on the dried blood spot to flag elevated glutarylcarnitine, C5DC. The marker is specific for GA-1 among the conditions in the routine panel. Confirmation uses urine organic acids showing elevated glutaric acid and 3-hydroxyglutaric acid (in high excretors), plasma acylcarnitines, and GCDH sequencing.

GA-1 is on the federal Recommended Uniform Screening Panel and is universally screened in the United States.

What management looks like

Standard of care has two components, both started in the first weeks of life when the diagnosis is made. The first is a lysine-restricted diet using a lysine-free, tryptophan-reduced medical formula combined with measured natural protein. The metabolic dietitian calibrates the protein restriction to maintain growth and amino acid sufficiency. L-carnitine supplementation is continuous and lifelong, reducing the proportion of glutaryl-CoA that escapes the carnitine shuttle as free glutaric acid.

The second component is the emergency protocol. Any febrile illness, vomiting, reduced intake, surgery, or other potential catabolic stress triggers prompt intravenous dextrose at high infusion rates, additional carnitine, and protein elimination for 24 to 48 hours, started early in the illness. The emergency protocol is the part of management that prevents the encephalopathic crisis. Families travel with an emergency letter that primary care and emergency department physicians can read on arrival.

Outcomes change dramatically when both components are in place from the neonatal period. Cohort studies from Germany (Kolker and colleagues), the United States, and Canada report rates of dystonic movement disorder below 10 percent in screen-detected children managed at experienced metabolic centers, compared with 80 to 90 percent in unscreened or late-diagnosed cohorts. The Pennsylvania Amish experience, where the founder population was identified before universal screening and where Holmes Morton's metabolic clinic provided the management infrastructure, was an early demonstration that the same management framework worked in a previously decimated population.

Liver transplantation has been reported in selected cases and reduces metabolite production by replacing the largest tissue source of catabolic enzyme expression. Transplant does not reverse established striatal injury and is not standard.

Once striatal injury has occurred, treatment is supportive. Antispasticity and antidystonic medications, physical therapy, and assistive technology address the movement disorder. The neurological injury itself is not reversible with current treatment.

What this looks like for a family

A baby is born and the heel-prick is sent. On day 4, the state lab reports elevated C5DC. On day 5, urine organic acids and GCDH sequencing confirm GA-1. The metabolic team starts lysine-restricted formula and L-carnitine. The family receives the emergency letter, the protocol for febrile illness, and the contact information for the clinic that will manage the next eighteen years. The first febrile illness, when it comes at 14 months, is managed at the emergency department with intravenous dextrose and protein elimination. The illness passes. There is no encephalopathic crisis.

That child grows up with the same diet, the same supplements, the same emergency protocol, and a striatum that stayed intact through every illness. Without screening, the same child would have been a healthy macrocephalic infant who returned from a febrile illness at 18 months with a movement disorder that the family would never see resolve.

The screen rewrote the clinical anchor. The dietary intervention plus the emergency protocol is the medicine. The medicine has to be there before the first illness for the screen to matter.